The triple-agonist studied for metabolic rate and body composition.
Retatrutide is a synthetic peptide studied as a triple agonist, engaging GLP-1, GIP, and glucagon receptors simultaneously. Research suggests GLP-1 and GIP receptor activity may support insulin secretion and appetite-regulation pathways, while concurrent glucagon receptor engagement is of particular interest for its association with increased energy expenditure. Clinical research literature has examined this combined mechanism for its potential relevance to body composition and metabolic rate studies. Intended for research purposes.
Shop now ← Back to shop
Retatrutide is studied as a triple agonist, engaging GLP-1, GIP, and glucagon receptors simultaneously. GLP-1 and GIP activity are studied for supporting insulin secretion and appetite regulation, while concurrent glucagon receptor engagement is of particular research interest for its association with increased energy expenditure — a combined mechanism studied for its relevance to body composition.
Research Use Only. These products have not been evaluated or approved by the FDA for use as drugs, therapeutics, diagnostics, or dietary supplements, and are not intended for administration to humans or animals. No product description or mechanism-of-action information constitutes a health claim or therapeutic endorsement. Any clinical use is at the sole discretion of a licensed healthcare provider in compliance with applicable laws. Individual results may vary.